Novartis Ag

Novassay S.a.

Franz Kricek

Premji Meghani

Beda Stadler

Monique Vogel

A compound of Formula 1  or a tautomer thereof; and Processes to prepare said compounds and novel intermediates are also claimed. Such compound finds utility in treating neuropathic pain and disorders of the central nervous system.

&#x3b3;-aminobutyric acid (GABA) analogues for the treatment of pain and other disorders

A compound of Formula (1) wherein Rrepresents hydrogen, halo, a C1-C4 alkyl group, a C1-C4 alkylhalide group, a C1-C4 alkoxy-C2-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group or a C3-C7 cyclo alkyl group; Rrepresents Formula (1)' or Formula (1)&#x2033; a tautomer thereof; and Rrepresents hydrogen, a C1-C4 alkyl group, a C1-C4 alkoxy-C2-C4 alkyl group or a C7 cyclo alkyl group; or a pharmaceutically acceptable salt or solvate thereof. Processes to prepare said compounds and novel intermediates are also claimed. Such compound finds utility in treating neuropathic pain and disorders of the central nervous system. 

Antibodies and antibody fragments which are anti-idiotypic to an antibody that interferes with the binding of the C&#x3b5;3 region of IgE to its high affinity receptor (mimobodies), particularly, which are anti-idiotypic to BSW17 (BSW17-mimobodies) are described, as well as their use as pharmaceuticals, especially vaccines, in the treatment of IgE-mediated diseases.

Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobulin E to its high affinity receptors

Disclosed are compositions for treating allergies that include either BSW17 mimotope peptides or antibodies raised against BSW17 mimotope peptides. Also disclosed are methods for the treatment of allergies which involve administration of BSW17 mimotope peptides or the administration of antibodies raised against BSW17 mimotope peptides.

Growing community of inventors

Biedermannsdorf, Austria

Franz Kricek